Charles Schwab Investment Management Inc Entrada Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $521 Billion
- Q1 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 192,717 shares of TRDA stock, worth $1.39 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
192,717
Previous 197,127
2.24%
Holding current value
$1.39 Million
Previous $3.41 Million
48.88%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding TRDA
# of Institutions
111Shares Held
28.7MCall Options Held
8.2KPut Options Held
2.3K-
Baker Bros. Advisors LP New York, NY4.87MShares$35.2 Million0.52% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$31.9 Million27.61% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$31.7 Million57.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.74MShares$19.8 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X02.12MShares$15.3 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $227M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...